Skip to main content
    C

    CryoCell International Inc (CCEL)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • AMEX

    $4.52
    -0.33 (-6.80%)

    Market Cap: $39.10M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CryoCell International Inc (CCEL) Financials: Revenue, Profit and Cash Flow

    Updated Oct 9, 2026. Financial statements from company filings, amounts in US dollars.

    CryoCell International reported revenue of $31.57M for the fiscal year ended Nov 30, 2025, down 1.3% from the year before. That year, net income was -$2.43M with a net margin of -7.7%, operating cash flow was $5.48M and free cash flow was $5.25M. The quarter ended Aug 31, 2026 had revenue of $7.82M and net income of $1.27M.

    Revenue and Margins

    The operating margin was 1.5% in the fiscal year ended Nov 2025. Over the 9 years to Nov 2025, revenue grew from $23.13M, a compound annual rate of 3.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Nov 2025$31.57M-1.3%76.6%1.5%-7.7%
    Nov 2024$31.99M+2.0%75.2%10.9%1.3%
    Nov 2023$31.34M+3.3%73.2%-39.3%-30.4%
    Nov 2022$30.34M+5.0%71.0%13.3%9.1%
    Nov 2021$28.88M-7.3%68.9%13.9%7.2%
    Nov 2020$31.15M-2.1%69.0%24.6%11.6%
    Nov 2019$31.82M+8.9%68.5%15.9%7.2%
    Nov 2018$29.22M+10.7%70.8%17.8%-2.9%
    Nov 2017$26.39M+14.1%74.5%19.0%8.8%
    Nov 2016$23.13MN/A75.0%1.9%-5.7%
    Annual, fiscal years ended Nov 2016 to Nov 2025

    Income Statement

    In the fiscal year ended Nov 2025, the company posted a net loss after a profit the year before. In the quarter ended Aug 2026, net income rose 69.5% from the same quarter a year earlier.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018Nov 2017Nov 2016
    Revenue$31.57M$31.99M$31.34M$30.34M$28.88M$31.15M$31.82M$29.22M$26.39M$23.13M
    Cost of revenue$7.38M$7.95M$8.39M$8.79M$8.99M$9.66M$10.04M$8.54M$6.72M$5.77M
    Gross profit$24.19M$24.04M$22.95M$21.54M$19.90M$21.49M$21.78M$20.68M$19.66M$17.35M
    Research and development$376.26K$1.24M$1.17M$384.79K$49.87K$23.85K$30.14K$91.84K$41.16K$53.10K
    Operating income$482.39K$3.48M-$12.30M$4.02M$4.02M$7.66M$5.06M$5.19M$5.01M$433.59K
    Net income-$2.43M$402.10K-$9.52M$2.77M$2.08M$3.62M$2.29M-$854.82K$2.32M-$1.32M
    EBITDA$1.12M$5.71M-$10.40M$6.67M$5.39MN/A$5.61M$5.59M$5.28MN/A
    Fiscal years ended Nov 2016 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Revenue$7.82M$7.78M$7.68M$7.84M$7.83M$7.93M$7.97M$8.02M$8.07M$8.04M$7.85M$7.88M
    Gross profit$6.21M$6.10M$6.03M$6.11M$6.02M$6.07M$5.98M$6.29M$5.94M$6.02M$5.79M$5.85M
    Operating income$2.19M$1.20M$765.13K-$3.97M$1.90M$1.49M$1.06M-$122.35K$1.39M$1.39M$821.22K-$16.18M
    Net income$1.27M$554.59K$47.11K-$3.82M$749.41K$355.79K$282.86K-$1.86M$1.05M$655.79K$556.24K-$11.19M
    Last 12 quarters

    Balance Sheet

    As of Nov 2025, total debt of $11.53M exceeded cash and equivalents by $11.21M. Shareholder equity was negative, at -$18.61M, as total liabilities of $80.33M exceeded total assets of $61.73M.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018Nov 2017Nov 2016
    Total assets$61.73M$64.68M$61.22M$64.89M$60.66M$46.20M$42.89M$42.39M$23.91M$19.54M
    Current assets$11.76M$12.55M$9.45M$9.61M$15.78M$18.56M$15.39M$14.76M$12.74M$9.01M
    Cash and equivalents$319.03K$560.96K$406.07K$1.70M$8.26M$10.36M$6.54M$6.04M$6.28M$3.50M
    Total liabilities$80.33M$77.89M$72.25M$66.41M$56.48M$48.87M$49.84M$51.30M$36.41M$34.95M
    Short-term debt$2.48M$3.69M$1.39M$2.42M$1.90M$3.10M$3.10M$3.10M$2.00M$2.00M
    Long-term debt$9.05M$9.19M$9.31M$9.45M$875.00K$3.72M$7.28M$11.27M$6.72M$9.24M
    Shareholder equity-$18.61M-$13.22M-$11.03M-$1.52M$4.18M-$2.67M-$6.95M-$8.91M-$12.50M-$15.41M
    Fiscal years ended Nov 2016 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total assets$62.30M$60.71M$60.88M$61.73M$63.17M$64.44M$64.38M$64.68M$62.93M$62.57M$61.71M$61.22M
    Total liabilities$78.70M$78.46M$79.29M$80.33M$78.00M$80.00M$79.04M$77.89M$72.49M$73.31M$72.05M$72.25M
    Cash and equivalents$1.43M$507.30K$249.67K$319.03K$265.21K$137.49K$223.12K$560.96K$197.44K$469.19K$247.11K$406.07K
    Shareholder equity-$16.39M-$17.76M-$18.40M-$18.61M-$14.83M-$15.56M-$14.66M-$13.22M-$9.56M-$10.74M-$10.34M-$11.03M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Nov 2025, free cash flow was 95.8% of operating cash flow. Dividends and share repurchases together came to 64.8% of it.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018Nov 2017Nov 2016
    Operating cash flow$5.48M$6.01M$8.92M$8.57M$7.93M$8.47M$6.29M$5.33M$5.72M$4.99M
    Capital expenditures$230.47K$2.40M$6.84M$12.17M$1.83M$99.96K$662.29K$446.16K$98.33K$342.98K
    Free cash flow$5.25M$3.61M$2.08M-$3.60M$6.09M$8.37M$5.63M$4.89M$5.62M$4.64M
    Dividends paid$3.23M$2.02M$0$7.67M$0N/AN/A$0$0$0
    Share repurchases$169.50K$1.42M$799.04K$1.82M$249.38K$0$992.24KN/A$446.62K$10.81M
    Investing cash flow-$975.33K-$4.88M-$8.14M-$15.28M-$6.95M$357.49K-$662.29K-$11.28M$93.03K-$369.73K
    Financing cash flow-$4.75M-$979.12K-$2.07M$147.86K-$3.07M-$5.00M-$5.13M$5.71M-$3.03M-$5.27M
    Fiscal years ended Nov 2016 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Operating cash flow$1.14M$1.85M$651.83K$1.28M$2.54M$707.01K$954.06K$2.16M$2.44M$1.77M-$356.87K$3.34M
    Capital expenditures$101.88K$32.70K$67.06K$67.23K$38.79K$62.41K$62.05K$8.35K$185.71K$1.75M$457.72K$1.71M
    Free cash flow$1.04M$1.81M$584.76K$1.21M$2.50M$644.61K$892.01K$2.15M$2.25M$21.55K-$814.59K$1.63M
    Last 12 quarters

    Frequently Asked Questions About CCEL

    What is CryoCell International's annual revenue?

    CryoCell International reported revenue of $31.57M for the fiscal year ended Nov 30, 2025.

    How fast is CryoCell International's revenue growing?

    Revenue was down 1.3% for the fiscal year ended Nov 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.3%.

    Is CryoCell International profitable?

    No. CryoCell International reported net income of -$2.43M for the fiscal year ended Nov 30, 2025, with a net margin of -7.7%.

    How much free cash flow does CCEL generate?

    For the fiscal year ended Nov 30, 2025, operating cash flow of $5.48M minus capital expenditures of $230.47K produced free cash flow of $5.25M.

    How much debt does CryoCell International have?

    The balance sheet dated Nov 30, 2025 reported long-term debt of $9.05M, short-term debt of $2.48M and cash and equivalents of $319.03K.